Drug profile · INN
tirbanibulin
KLISYRI
tirbanibulin (KLISYRI) is a tyrosine-protein kinase src inhibitor. Associated with S.A.. Route of administration: topical. Current US regulatory status: approved.
Drug details — tirbanibulin
- US status
- approved
- Class
- Dermatologicals (D06)
- Route
- TOPICAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
tirbanibulin (KLISYRI) is a tyrosine-protein kinase src inhibitor. Associated with S.A.. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase SRC inhibitor
Primary target: Proto-oncogene tyrosine-protein kinase Src
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tirbanibulin?
tirbanibulin (KLISYRI) is a tyrosine-protein kinase src inhibitor. Associated with S.A.. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for tirbanibulin?
KLISYRI is a marketed brand name for tirbanibulin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tirbanibulin?
tirbanibulin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.